Jul 18, 2022 8:00am EDT MAIA Biotechnology Doses First Patient With THIO in Phase 2 Trial (THIO-101) for Non-Small Cell Lung Cancer
Jun 14, 2022 8:14am EDT MAIA Biotechnology, Inc. Announces Research Collaboration with Nationwide Children’s Hospital to Evaluate THIO in Combination with Standard-of-Care Cancer Therapies
May 19, 2022 8:45am EDT MAIA Biotechnology, Inc. Establishes Wholly Owned Subsidiaries in Romania and Australia to Support Global Development of THIO
Apr 26, 2022 8:37am EDT MAIA Biotechnology, Inc. Announces FDA Orphan Drug Designation for THIO for the Treatment of Hepatocellular Carcinoma (HCC)
Mar 16, 2022 8:07am EDT MAIA Biotechnology, Inc. Announces $2.4 Million Financing to Advance Targeted Immuno-Oncology Studies
Mar 15, 2022 8:00am EDT MAIA Biotechnology, Inc. Announces HREC Approval in Australia for its THIO-101 Phase 2 Trial for NSCLC
Nov 09, 2021 8:04am EST MAIA Biotechnology, Inc. Announces Poster Presentation at the Society for Immunotherapy of Cancer 36th Annual Meeting (SITC)
Sep 28, 2021 8:00am EDT MAIA Biotechnology, Inc. Announces the Appointment of Steven M. Chaouki to Its Board of Directors
